Literature DB >> 26587319

Interaction of tumor cells with infiltrating lymphocytes via CD70 and CD27 in clear cell renal cell carcinoma.

Melanie Ruf1, Holger Moch1, Peter Schraml1.   

Abstract

CD70 upregulation by hypoxia-inducible factor and CD27+ lymphocyte tumor infiltration are associated with worse survival in von Hippel-Lindau gene (VHL) mutated clear cell renal cell carcinoma (ccRCC). CD70/CD27 interaction is accompanied by high soluble CD27 levels in the sera of ccRCC patients suggesting that soluble CD27 is a potential predictive tool for anti-CD70 therapy.

Entities:  

Keywords:  CD27; CD70; clear cell renal cell carcinoma; soluble CD27; von Hippel-Lindau gene

Year:  2015        PMID： 26587319      PMCID： PMC4635726          DOI： 10.1080/2162402X.2015.1049805

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  7 in total

1.  Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions.

Authors:  Kiki Tesselaar; Ramon Arens; Gijs M W van Schijndel; Paul A Baars; Martin A van der Valk; Jannie Borst; Marinus H J van Oers; René A W van Lier
Journal:  Nat Immunol       Date:  2002-12-09       Impact factor: 25.606

2.  pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma.

Authors:  Melanie Ruf; Christiane Mittmann; Anna M Nowicka; Arndt Hartmann; Thomas Hermanns; Cédric Poyet; Maries van den Broek; Tullio Sulser; Holger Moch; Peter Schraml
Journal:  Clin Cancer Res       Date:  2015-02-15       Impact factor: 12.531

3.  Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma.

Authors:  Qiong J Wang; Ken-Ichi Hanada; Paul F Robbins; Yong F Li; James C Yang
Journal:  Cancer Res       Date:  2012-10-15       Impact factor: 12.701

4.  Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity.

Authors:  Jianping Huang; Caroline Jochems; Austin M Anderson; Tara Talaie; Alessandra Jales; Ravi A Madan; James W Hodge; Kwong Y Tsang; David J Liewehr; Seth M Steinberg; James L Gulley; Jeffrey Schlom
Journal:  J Immunol       Date:  2013-05-15       Impact factor: 5.422

Review 5.  Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology.

Authors:  Martijn A Nolte; Ronald W van Olffen; Klaas P J M van Gisbergen; René A W van Lier
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 6.  CD70 as a therapeutic target in human malignancies.

Authors:  Iqbal S Grewal
Journal:  Expert Opin Ther Targets       Date:  2008-03       Impact factor: 6.902

Review 7.  Progress of molecular targeted therapies for advanced renal cell carcinoma.

Authors:  Alessandro Conti; Matteo Santoni; Consuelo Amantini; Luciano Burattini; Rossana Berardi; Giorgio Santoni; Stefano Cascinu; Giovanni Muzzonigro
Journal:  Biomed Res Int       Date:  2013-09-04       Impact factor: 3.411
  7 in total
  4 in total

Review 1.  Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

Authors:  Erika Vacchelli; Norma Bloy; Fernando Aranda; Aitziber Buqué; Isabelle Cremer; Sandra Demaria; Alexander Eggermont; Silvia Chiara Formenti; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-07-25       Impact factor: 8.110

Review 2.  Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Authors:  Mariona Cabo; Rienk Offringa; Laurence Zitvogel; Guido Kroemer; Aura Muntasell; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-30       Impact factor: 8.110

3.  CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment.

Authors:  Mathieu Seyfrid; William Thomas Maich; Vaseem Muhammad Shaikh; Nazanin Tatari; Deepak Upreti; Deween Piyasena; Minomi Subapanditha; Neil Savage; Dillon McKenna; Nicholas Mikolajewicz; Hong Han; Chirayu Chokshi; Laura Kuhlmann; Amanda Khoo; Sabra Khalid Salim; Blessing Archibong-Bassey; William Gwynne; Kevin Brown; Nadeem Murtaza; David Bakhshinyan; Parvez Vora; Chitra Venugopal; Jason Moffat; Thomas Kislinger; Sheila Singh
Journal:  J Immunother Cancer       Date:  2022-01       Impact factor: 13.751

4.  A 44-gene set constructed for predicting the prognosis of clear cell renal cell carcinoma.

Authors:  Yonggang Wang; Yao Wang; Feng Liu
Journal:  Int J Mol Med       Date:  2018-09-26       Impact factor: 4.101
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.